[C:1]1([C:7]2[O:8][C:9]3[CH2:10][NH:11][CH2:12][CH2:13][C:14]=3[N:15]=2)[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.Cl.[OH:17][CH:18]([CH2:22][CH3:23])[C:19](O)=[O:20].C(N(CC)CC)C.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F>CN(C=O)C.C(Cl)Cl>[OH:17][CH:18]([CH2:22][CH3:23])[C:19]([N:11]1[CH2:12][CH2:13][C:14]2[N:15]=[C:7]([C:1]3[CH:2]=[CH:3][CH:4]=[CH:5][CH:6]=3)[O:8][C:9]=2[CH2:10]1)=[O:20]1.14 g (4.80 mmol) 2-phenyl-4,5,6,7-tetrahydro-oxazolo[5,4-c]pyridine×HCl, 500.00 g (4.80 mmol) 2-hydroxybutanoic acid are placed in 10 mL DMF. Then 2.60 mL (18.51 mmol) triethylamine and 2.10 g (5.52 mmol) HATU are added and the mixture is stirred for 30 min at RT. The DMF is eliminated i.V., the residue is added to DCM and extracted 1 time each with 5% potassium hydrogen carbonate solution and 1N HCl. The solvent of the org. phase is eliminated in vacuo and the residue is purified on silica gel. (Eluant: cyclohexane/EA).
読み込み中…
